{
    "Trade/Device Name(s)": [
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K203089",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200876"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QDK"
    ],
    "Summary Letter Date": "August 17, 2021",
    "Summary Letter Received Date": "March 8, 2021",
    "Submission Date": "July 19, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor/applicator",
        "Dexcom G6 BLE transmitter",
        "Mobile CGM display (embedded app module within third party host app)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Glucose Program CGM System with mobile software module embedded in third-party host app for diabetes management",
    "Indications for Use Summary": "Real-time continuous glucose monitoring system indicated for management of diabetes in persons age 2 years and older, intended to replace fingerstick blood glucose testing for treatment decisions in patients not at significant risk of severe hypoglycemia and to autonomously communicate with digitally connected devices.",
    "fda_folder": "Clinical Chemistry"
}